In a report released today, Raju Prasad from William Blair downgraded Bluebird Bio (BLUE) to Hold. The company’s shares closed last Tuesday at $25.62, close to its 52-week low of $24.24.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 24.8% and a 61.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Crispr Therapeutics AG.
Bluebird Bio has an analyst consensus of Hold, with a price target consensus of $44.15, implying a 70.2% upside from current levels. In a report issued on February 16, Mizuho Securities also downgraded the stock to Hold with a $34.00 price target.
See today’s analyst top recommended stocks >>
Bluebird Bio’s market cap is currently $1.7B and has a P/E ratio of -2.40. The company has a Price to Book ratio of 1.15.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
